Dr John Mascarenhas – "I'm a believer"

[huntingonthebluffs]

Found this interview on Patient Power educational and another glimpse of what we have in Imetelstat.

Current Myelofibrosis Research, Clinical Trials, and Treatments (Published on July 6, 2021)

https://patientpower.info/experts-share ... ipt-anchor

Towards the end of the interview Dr. Mascarenhas discusses Imetelstat and states: “For one, I'm a believer, I do think that the drug has activity and has the potential to improve survival, which is a concern for patients who fail ruxolitinib. And there are a number of studies, unfortunately, that show us that survival can be compromised in that setting. So, a drug that can improve that survival would be very important. This is a randomized Phase III study where the primary endpoint is overall survival, and that in itself is quite unique and speaks volumes about where we're going with this research endeavor in which it's not simply focused on spleen and symptom, which are not unimportant, but also in other important things like living longer.”